International Clinical Trial: A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07137598) titled 'A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)' on Aug. 15.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).

Primary Sponsor: Hoffmann-La Roche

Condition: Rheumatoid Arthritis

Intervention: Drug: Afimkibart

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: No...